Chongqing Pharscin Pharmaceutical Co Ltd
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, soft capsules, powder injections, freeze-dried powders, injections, chemical raw materials, and small volume injections. It provides its products for the treatment of CNS, digestion, otolaryngology, oncology, cardiovascular, an… Read more
Chongqing Pharscin Pharmaceutical Co Ltd - Asset Resilience Ratio
Chongqing Pharscin Pharmaceutical Co Ltd (002907) has an Asset Resilience Ratio of 14.54% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Chongqing Pharscin Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Chongqing Pharscin Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥290.43 Million | 14.54% |
| Total Liquid Assets | CN¥290.43 Million | 14.54% |
Asset Resilience Insights
- Moderate Liquidity: Chongqing Pharscin Pharmaceutical Co Ltd has 14.54% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Chongqing Pharscin Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Chongqing Pharscin Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Chongqing Pharscin Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Chongqing Pharscin Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.29% | CN¥120.61 Million | CN¥1.92 Billion | +10.63pp |
| 2023-12-31 | -4.34% | CN¥-80.31 Million | CN¥1.85 Billion | -3.32pp |
| 2022-12-31 | -1.02% | CN¥-18.97 Million | CN¥1.87 Billion | -5.57pp |
| 2021-12-31 | 4.55% | CN¥80.61 Million | CN¥1.77 Billion | +1.64pp |
| 2020-12-31 | 2.91% | CN¥50.07 Million | CN¥1.72 Billion | -8.89pp |
| 2019-12-31 | 11.80% | CN¥193.25 Million | CN¥1.64 Billion | -8.08pp |
| 2017-12-31 | 19.88% | CN¥176.00 Million | CN¥885.15 Million | -- |